Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Takeda, PCI partner to launch lung cancer drug

Targeted once-daily tablet moves from molecule development, manufacture and clinical trial supply to U.S. commercial launch at PCI’s Tredegar contained facility.

Targeted one-daily tablet moves from molecule development, manufacture and clinical trial supply to U.S. commercial launch at PCI’s Tredegar contained facility.
Targeted one-daily tablet moves from molecule development, manufacture and clinical trial supply to U.S. commercial launch at PCI’s Tredegar contained facility.

Earlier this year, Takeda Pharmaceutical Co. Ltd. announced that its ALUNBRIG™ (brigatinib) had received Accelerated Approval from the FDA for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. ALUNBRIG, a once-daily tablet, is a targeted cancer medicine discovered by ARIAD Pharmaceuticals, Inc., which was acquired by Takeda in February 2017.

The launch of ALUNBRIG also represented a significant milestone for PCI Pharma Services’ (PCI) contained manufacturing facility in Tredegar (Wales, U.K.), which supported Takeda—through ARIAD— in the development, manufacture, clinical trial supply and U.S. commercial launch of ALUNBRIG.

PCI reports that ALUNBRIG represents the first molecule to complete the development-to-commercial launch from Tredegar. PCI now runs multiple projects within this contained facility, and expects a high percentage of these to achieve regulatory approval and commercial launch in global markets.

Takeda chose to partner with PCI for its specialist team of formulation scientists and the Tredegar site, which processes molecules with an Occupational Exposure Limit (OEL) as low as 0.01µg/m3 while eliminating the need for Personal Protective Equipment (PPE) for routine operations.

PCI’s Richard Yarwood, Senior Vice President, International, said, “This is a significant milestone for our Tredegar site.The engineering solutions and geometric scale-up provided by our equipment trains ensured a smooth transition of ALUNBRIG through development, scale-up and ultimately commercial supply for Takeda.”

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging